A
Acumen Pharmaceuticals, Inc. (ABOS)
NMS – Real Time Price. Currency in USD
2.48
-0.09 (-3.50%)
At close: May 12, 2026, 4:00 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NMS – Real Time Price. Currency in USD
2.48
-0.09 (-3.50%)
At close: May 12, 2026, 4:00 PM EDT
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer’s disease. It focuses on advancing a targeted immunotherapy drug candidate, sabirnetug (ACU193), which is in its Phase 2 ALTITUDE-AD clinical trial to target toxic soluble amyloid beta oligomers. Acumen Pharmaceuticals, Inc. has a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of Sabirnetug, as well as with JCR Pharmaceuticals Co. Ltd for the development of Aß oligomer-targeted enhanced brain delivery therapy for the treatment of Alzheimer’s disease. The company was incorporated in 1996 and is headquartered in Newton, Massachusetts.
| Name | Position |
|---|---|
| Dr. Caleb E. Finch Ph.D. | Co-Founder |
| Dr. Grant A. Krafft Ph.D. | Co-Founder |
| Dr. James Doherty Ph.D. | President & Chief Development Officer |
| Dr. William L. Klein Ph.D. | Co-Founder |
| Mr. Daniel J. O'Connell M.B.A. | CEO & Director |
| Mr. Derek M. Meisner Esq., J.D. | Chief Legal Officer & Corporate Secretary |
| Mr. Matt Zuga | CFO & Chief Business Officer |
| Mr. Russell Barton M.S. | Chief Operating Officer |
| Ms. Alex Braun M.B.A. | VP & Head of Investor Relations |
| Ms. Kelly Carranza | Senior Vice President of Finance & Accounting and Corporate Controller |
| Date | Type | Document |
|---|---|---|
| 2026-05-12 | 8-K | abos-20260512.htm |
| 2026-04-23 | DEFA14A | defa14a2026.htm |
| 2026-03-30 | CORRESP | filename1.htm |
| 2026-03-26 | 8-K | abos-20260326.htm |
| 2026-03-26 | 10-K | abos-20251231.htm |
| 2026-03-16 | 8-K | abos-20260313.htm |
| 2026-01-12 | 8-K | abos-20260112.htm |
| 2025-11-12 | 8-K | abos-20251112.htm |
| 2025-11-10 | 8-K | abos-20251106.htm |
| 2025-08-12 | 8-K | abos-20250812.htm |